Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the
diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography.
2. To demonstrate that RG1068-enhanced MRCP improves image quality relative to unenhanced
MRCP in patients with unexplained acute recurrent pancreatitis (ARP) and chronic
pancreatitis.
3. To evaluate if the use of RG1068-enhanced MRCP improves structural delineation of the
pancreatic duct as compared to the non-enhanced MRCP.
4. To assess pancreatic exocrine function by quantifying pancreatic fluid output into the
duodenum and the apparent diffusion coefficient of the pancreas.